Jessica Ross Steps Down as Frontdoor CFO, Jason Bailey Takes Over
New Appointment: Frontdoor has appointed Jason Bailey as the new senior VP and CFO, succeeding Jessica Ross.
Transition Period: Jessica Ross will remain with the company as an advisor to the CEO until December 31 to facilitate a smooth transition.
Previous Role: Before his new role, Jason Bailey served as VP of finance at Frontdoor.
Effective Date: Jessica Ross's resignation as CFO is effective November 10.
Trade with 70% Backtested Accuracy
Analyst Views on FTDR
About FTDR
About the author

Frontdoor to Release Q4 and Full-Year 2025 Financial Results
- Earnings Release Schedule: Frontdoor, Inc. will announce its fourth-quarter and full-year 2025 financial results on February 26, 2026, at 7:30 a.m. Central Time, which is expected to attract investor attention.
- Participation Details: Investors can join the conference call by dialing 888.506.0062 (or 973.528.0011 for international participants) with conference ID 744607, ensuring timely access to the company's latest financial information.
- Webcast Availability: The company will provide a webcast for participants to register and view a slide presentation, enhancing transparency and boosting investor confidence in the company's performance.
- Replay Accessibility: After the call, a replay will be available for approximately 60 days, allowing participants to access key information by calling 877.481.4010 (or 919.882.2331 for international calls), ensuring that those unable to attend live can still stay informed.

Daily Upgrade Report for Validea's Joel Greenblatt Strategy - December 12, 2025
Validea's Earnings Yield Investor Model: The model, based on Joel Greenblatt's strategy, evaluates companies with high return on capital and earnings yields, resulting in significant rating changes for several stocks.
Clorox Company (CLX): The stock rating improved from 60% to 80%, indicating strong interest based on its fundamentals and valuation in the Personal & Household Products industry.
Catalyst Pharmaceuticals (CPRX): This mid-cap value stock saw its rating rise from 50% to 90%, reflecting strong fundamentals and valuation in the Biotechnology & Drugs sector.
Playtika Holding Corp (PLTK): The small-cap growth stock's rating surged from 70% to 100%, showcasing exceptional fundamentals and valuation in the Software & Programming industry.






